94 related articles for article (PubMed ID: 18094622)
1. Mouse embryonic stem cells induce targeted DNA demethylation within human MAGE-A1 transgenes.
Loriot A; Sterpin C; De Backer O; De Smet C
Epigenetics; 2008; 3(1):38-42. PubMed ID: 18094622
[TBL] [Abstract][Full Text] [Related]
2. Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.
Loriot A; De Plaen E; Boon T; De Smet C
J Biol Chem; 2006 Apr; 281(15):10118-26. PubMed ID: 16497664
[TBL] [Abstract][Full Text] [Related]
3. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells.
De Smet C; Loriot A; Boon T
Mol Cell Biol; 2004 Jun; 24(11):4781-90. PubMed ID: 15143172
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
Kim KH; Choi JS; Kim IJ; Ku JL; Park JG
World J Gastroenterol; 2006 Sep; 12(35):5651-7. PubMed ID: 17007017
[TBL] [Abstract][Full Text] [Related]
5. Expression of MAGE-A1 mRNA is associated with gene hypomethylation in hepatocarcinoma cell lines.
Xiao J; Chen HS; Fei R; Cong X; Wang LP; Wang Y; Jiang D; Wei L; Wang Y
J Gastroenterol; 2005 Jul; 40(7):716-21. PubMed ID: 16082588
[TBL] [Abstract][Full Text] [Related]
6. Demethylation of MAGE promoters during gastric cancer progression.
Honda T; Tamura G; Waki T; Kawata S; Terashima M; Nishizuka S; Motoyama T
Br J Cancer; 2004 Feb; 90(4):838-43. PubMed ID: 14970862
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
De Smet C; Lurquin C; Lethé B; Martelange V; Boon T
Mol Cell Biol; 1999 Nov; 19(11):7327-35. PubMed ID: 10523621
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Suzuki T; Yoshida K; Wada Y; Hamai Y; Sentani K; Oue N; Yasui W
Oncol Rep; 2007 Aug; 18(2):329-36. PubMed ID: 17611652
[TBL] [Abstract][Full Text] [Related]
9. [Expression of MAGE-A1 in human hepatoma cell lines associated with genic hypomethylation].
Xiao J; Chen HS; Fei R; Cong X; Wang Y; Jiang D; Wei L; Wang Y
Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):351-4. PubMed ID: 15918969
[TBL] [Abstract][Full Text] [Related]
10. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Wischnewski F; Pantel K; Schwarzenbach H
Mol Cancer Res; 2006 May; 4(5):339-49. PubMed ID: 16687489
[TBL] [Abstract][Full Text] [Related]
11. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
12. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
[TBL] [Abstract][Full Text] [Related]
13. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.
Grau E; Oltra S; Martínez F; Orellana C; Cañete A; Fernández JM; Hernández-Martí M; Castel V
J Cancer Res Clin Oncol; 2009 Apr; 135(4):523-31. PubMed ID: 18820946
[TBL] [Abstract][Full Text] [Related]
14. The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies.
Suyama T; Ohashi H; Nagai H; Hatano S; Asano H; Murate T; Saito H; Kinoshita T
Leuk Res; 2002 Dec; 26(12):1113-8. PubMed ID: 12443884
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of methylation of MAGE-A1 and-A3 promoters and expression of DNA methyltransferase in patients with laryngeal squamous cell carcinoma.
Liu S; Zhao Y; Xu Y; Sang M; Zhao R; Gu L; Shan B
Am J Otolaryngol; 2020; 41(1):102318. PubMed ID: 31732299
[TBL] [Abstract][Full Text] [Related]
16. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F; Friese O; Pantel K; Schwarzenbach H
Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
[TBL] [Abstract][Full Text] [Related]
17. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
18. Methylated CpG points identified within MAGE-1 promoter are involved in gene repression.
Serrano A; García A; Abril E; Garrido F; Ruiz-Cabello F
Int J Cancer; 1996 Nov; 68(4):464-70. PubMed ID: 8945617
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation profiling of 30 genes in human malignant melanoma.
Furuta J; Umebayashi Y; Miyamoto K; Kikuchi K; Otsuka F; Sugimura T; Ushijima T
Cancer Sci; 2004 Dec; 95(12):962-8. PubMed ID: 15596045
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
Schwarzenbach H; Eichelser C; Steinbach B; Tadewaldt J; Pantel K; Lobanenkov V; Loukinov D
BMC Cancer; 2014 Nov; 14():796. PubMed ID: 25363021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
